Hansa Biopharma AB

Hansa Biopharma’s Phase III ConfIdeS results on the enzyme imflidas will be presented as a late‑breaking abstract at the American Transplant Congress, potentially advancing kidney transplant therapy and regulatory prospects.

Hansa Biopharma AB’s investigational enzyme imlifidase has achieved a major milestone in a Phase III trial, meeting the primary endpoint and paving the way for a potential US approval and significant expansion of the company’s operations in the worl…

Hansa Biopharma’s lead product, imlifidase, has achieved positive Phase-3 results in a pivotal trial for kidney transplantation, demonstrating a significant reduction in anti-HLA antibodies and a favorable safety profile.

Hansa Biopharma AB, a Swedish biopharmaceutical company, is poised for success in treating rare diseases and transplant rejection, with a solid financial foundation and a focus on innovation and patient care.

Hansa Biopharma AB reports positive clinical results for its immunomodulatory enzyme imlifidase in combination with gene therapy for Duchenne muscular dystrophy treatment.

Hansa Biopharma AB reports positive results from a study using imlifidase to treat Duchenne muscular dystrophy, paving the way for improved gene therapy efficacy.